advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Conditions
Interventions
Senapalli Group:Senaparib Capsules
Sponsors
Henan Provincial People's Hospita,medical
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Newly diagnosed patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (based on local pathological diagnosis); 2.Patients who achieve CR/PR after receiving first-line paclitaxel platinum chemotherapy; 3.Age >= 18 years old; 4.Researchers evaluated the possibility of using the selpercatinib regimen for treatment; 5.The patient voluntarily joined this study. 6.For fertile patients, effective contraception should be used during the study period and within 90 days after the first administration of senaparib.
Exclusion criteria
Exclusion criteria: 1.Confirmed pregnant or lactating women; 2.Currently participating in any study with intervention measures outside of regular clinical practice; 3.The researchers judged other situations that were not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of adverse reactions(Adverse reaction events include type, incidence, grading (based on NCICTCAE V5.0 criteria), severity, and correlation with the drug); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival; | — |
Countries
China
Contacts
Public ContactZhu Qianyong
Henan Provincial People's Hospital
Outcome results
None listed